Contracts › 75N91023F00003
75N91023F00003: Prevent Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarkers Task Order Title: Sulforaphane for the Prevention of Malignant Mesothelioma
Awarded to The Institute for Cancer Research by National Institutes of Health (NIH).
$1.2Mobligated
$1.2Mpotential value
02 May 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N91023F00003 |
|---|---|
| Vehicle | 75N91019D00022 |
| Awardee | The Institute for Cancer Research |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NIH NCI |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | PA |
| Offers received | 1 |
| Period of performance | 03 May 2023 to 02 May 2027 |
| Potential end | 02 May 2027 |
| Estimated recompete solicitation | ~Q4 2026 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record